The Latest Breaking News from Tonix

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Wednesday.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a Chatham, New Jersey-based clinical-stage biopharmaceutical company, announced on Wednesday the issuance of a patent that forms the basis for the company's developmental vaccine against monkeypox and smallpox. 

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading higher Wednesday after the company announced that the United States Patent and Trademark Office issued a patent to Tonix titled, "Synthetic Chimeric Poxviruses."

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has 

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are rallying higher Thursday after the company announced the FDA has granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi syndrome.